Array biopharma inc (ARRY)
Income statement / Quarterly
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenue

64,677

82,549

56,910

35,437

66,367

42,218

29,746

33,778

33,280

44,523

39,271

43,205

43,047

35,430

16,197

12,320

6,601

26,919

6,069

6,011

7,773

14,066

14,228

25,415

9,955

18,377

15,833

20,663

19,113

23,228

22,131

19,046

17,841

16,501

18,513

Operating expenses
Cost of goods sold

1,042

786

195

59,374

0

0

0

10,092

7,432

9,026

8,845

5,444

5,847

5,663

6,212

6,977

12,140

13,098

12,177

11,441

10,756

13,110

10,658

7,006

8,624

7,909

6,539

6,260

5,291

6,266

6,444

7,636

6,617

7,382

7,281

Research and development

65,541

62,120

55,550

4,940

71,348

56,329

53,204

39,098

46,069

46,469

46,563

49,504

48,802

41,351

20,998

18,618

11,817

11,817

12,190

14,502

14,131

9,487

11,704

16,840

15,105

13,941

13,534

14,877

16,094

13,150

12,598

19,278

15,883

14,482

13,855

Selling, general and administrative

35,548

30,473

24,890

18,072

16,773

11,607

12,048

10,926

11,714

8,834

7,862

10,565

8,406

9,938

7,358

8,369

8,187

8,078

6,799

5,851

5,405

5,472

5,179

5,233

5,001

4,610

4,780

4,474

3,226

3,782

3,720

4,293

3,795

3,905

4,268

Total operating expenses

102,131

93,379

80,635

82,386

88,121

67,936

65,252

60,116

65,215

64,329

63,270

65,513

63,055

56,952

34,568

33,964

32,144

32,993

31,166

31,794

30,292

28,069

27,541

29,079

28,730

26,460

24,853

25,611

24,611

23,198

22,762

31,207

26,295

25,769

25,404

Gain on the Binimetinib and Encorafenib Agreements, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80,010

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-37,454

-10,830

-23,725

-46,949

-21,754

-25,718

-35,506

-26,338

-31,935

-19,806

-23,999

-22,308

-20,008

-21,522

-18,371

-20,003

54,467

-6,074

-25,097

-25,783

-22,519

-14,003

-13,313

-3,664

-18,775

-8,083

-9,020

-4,948

-5,498

30

-631

-12,161

-8,454

-9,268

-6,891

Other income (expense)
Interest income

2,912

2,286

1,524

1,395

1,295

1,255

525

286

228

212

70

76

76

51

40

32

15

8

13

16

22

23

16

14

18

12

11

15

8

3

6

19

31

136

220

Interest expense

2,863

2,818

2,580

2,407

2,361

2,833

3,213

3,152

3,095

3,107

2,979

2,782

2,743

2,693

2,656

2,616

2,577

2,545

2,509

2,470

2,435

2,428

2,383

2,802

2,837

2,860

2,759

2,155

2,678

3,836

2,955

3,268

4,172

4,175

3,892

Realized gain from marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,402

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

1,093

865

-67

Loss on extinguishment and conversion of notes

0

0

-

-

0

-6,457

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Realized gains on investments and other

-

-

-

-

-

-

-

-

785

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of notes payable

0

0

-65

-2,187

-100

-300

200

-500

-1,300

-600

-200

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment loss related to cost method investment

-

-

-

-

-

-

-

0

0

0

1,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other, net

-89

0

35

0

69

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

-40

-532

-1,086

-3,199

-1,097

-8,335

-2,488

-3,254

-3,382

-3,495

-4,609

-2,706

-2,667

-2,642

-2,616

7,269

3,840

-2,537

-2,496

-7,188

-2,413

-2,405

2,367

-19,481

-2,819

-2,848

2,748

3,082

2,670

3,833

2,949

9,589

3,048

3,174

3,739

Net loss

-37,494

-11,362

-24,811

-52,448

-22,851

-34,053

-37,994

-29,592

-35,317

-23,301

-28,608

-25,014

-22,675

-24,164

-20,987

-12,734

58,307

-8,611

-27,593

-28,237

-24,932

-16,408

-15,680

-17,649

-21,594

-10,931

-11,768

-

-8,168

-

-3,580

-21,750

-11,502

-12,442

-10,630

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,803

-

-

-

-

-

Change in unrealized gain (loss) on marketable securities

274

203

149

296

-81

-634

34

10

-36

-61

4

-7

51

-54

12

-9,793

-3,665

-1,059

14,520

-5

7

-8

10

-2

0

0

1

-2

1

1

-4

1

-4,304

-655

-567

Comprehensive loss

-37,220

-11,159

-24,662

-52,152

-22,932

-34,687

-37,960

-29,582

-35,353

-23,362

-28,604

-25,021

-22,624

-24,218

-20,975

-22,527

54,642

-9,670

-13,073

-28,242

-24,925

-16,416

-15,670

-17,651

-21,594

-10,931

-11,767

-8,032

-8,167

-3,802

-3,584

-21,749

-15,806

-13,097

-11,197

Weighted average shares outstanding – basic (in shares)

219,913

215,872

212,193

210,342

208,994

199,852

174,772

170,581

169,020

168,127

145,100

143,469

143,338

142,833

142,216

141,306

139,769

133,815

131,826

-

125,471

-

-

-

-

-

-

-

-

-

-

-

56,129

55,285

53,415

Weighted average shares outstanding – diluted (in shares)

219,913

215,872

212,193

210,342

208,994

199,852

174,772

170,581

169,020

168,127

145,100

143,469

143,338

142,833

142,216

134,862

166,265

133,815

131,826

-

125,471

-

-

-

-

-

-

-

-

-

-

-

56,129

55,285

53,415

Net loss per share – basic (in dollars per share)

-0.17

-0.05

-0.12

-0.24

-0.11

-0.17

-0.22

-0.17

-0.21

-0.14

-0.20

-0.17

-0.16

-0.17

-0.15

-0.08

0.42

-0.06

-0.21

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share – diluted (in dollars per share)

-0.17

-0.05

-0.12

-0.24

-0.11

-0.17

-0.22

-0.17

-0.21

-0.14

-0.20

-0.17

-0.16

-0.17

-0.15

-0.03

0.37

-0.06

-0.21

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding  basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

123,921

117,509

-

116,665

105,403

92,606

147,597

74,817

60,004

57

-

-

-

-

Net loss per share  basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.13

-0.13

-

-0.19

-0.10

-0.13

-0.10

-0.11

-0.06

-0.06

-0.39

-0.20

-0.23

-0.20

Product sales, net
Revenue

35,078

22,713

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product royalties
Revenue

937

-

-

-

0

-

-

5,973

1,665

10,545

1,661

1,914

857

1,105

0

0

99

20,099

169

1,472

4,287

9,287

10,065

23,386

6,848

14,016

12,476

17,622

15,970

19,195

18,462

15,595

13,907

11,131

12,793

Collaboration and license revenue
Revenue

19,493

50,924

-

-

41,616

19,823

-

5,962

5,530

6,030

6,289

7,873

5,249

6,977

6,574

6,640

5,162

6,820

5,900

4,539

3,486

4,779

4,163

2,029

3,107

4,361

3,357

3,041

3,143

4,033

3,669

3,451

3,934

5,370

5,720

Reimbursement revenue
Revenue

9,169

8,912

-

-

24,751

22,395

-

21,843

26,085

27,948

31,321

33,418

36,941

27,348

9,623

5,680

1,340

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-